Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
kynnið ykkur lyfjaupplýsingar deferoxamíns.
the product information of deferoxamine should be consulted.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
sjá lyfjaupplýsingar erlótíníbs varðandi skömmtun og gjöf erlótiníbs.
for the posology and method of administration of erlotinib, please refer to the full erlotinib prescribing information.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
byggt á aukningu lípasa og hækkun á meðalgildum lípasa sem gefið var til kynna í klínískum rannsóknum og eftir markaðssetningu, álítur prac að uppfæra skuli lyfjaupplýsingar og bæta
based on the signal on lipase increased and the events of increase in mean lipase values received from clinical trials and from postmarketing sources, the prac considered that the product information should be updated to add the adverse reactions ‘increased lipase’ and ‘increased amylase’ in section
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
by ggt á ofangreindu, er talið réttlætanlegt að skrá í lyfjaupplýsingar fyrir öll lyf sem innihalda levetiracetam að „heilakvilli“ komi mjög sjaldan fyrir.
based on the above, it is considered justified to document that cases of “encephalopathy” have been observed rarely in the product information of all levetiracetam-containing products.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
prac taldi að uppfæra ætti lyfjaupplýsingar aripíprazóls með upplýsingum um aukaverkunina „hiksti“ í kafla 4.8 í samantektinni á eiginleikum lyfsins þar sem ekki var hægt að útiloka áhrif aripíprazóls hjá tilkynntum tilvikum.
the prac considered that the product information of aripiprazole should be updated to include the adverse event ‘hiccups” in section 4.8 of the smpc, since a contributory role of aripiprazole in the reported cases could not be ruled out.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Þar af leiðandi ættu markaðsleyfishafar að bæta aukaverkuninni „rákvöðvalýsa“ undir líffæraflokkinn stoðkerfi og stoðvefur (tíðni „mjög sjaldgæf“) í lyfjaupplýsingar fyrir öll lyf sem innihalda levetiracetam.
therefore, the mahs should add the undesirable effect “rhabdomyolysis” under the soc musculoskeletal and connective tissue disorders (frequency ‘rare’) in the product information of all levetiracetam-containing products.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: